Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hematomas at the muscles where the EMG needle was inserted. These hematomas are considered a potential adverse effect of needle EMG.
The aim of the study is to determine whether needle EMG can be considered a safe procedure in this group of patients, without posing a risk of intramuscular hematoma formation.
Subjects must understand the nature of the study and must provide signed and dated written informed consent prior to conducting any study-related procedures
Willing and able to comply with all protocol procedures
subjects confirmed the daily (and recent) intake od direct anticoagulants in strandard dosing.
no other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is taken.
Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject
other antitrombotic drug therapy (e.g. acetylsalicyl acid, clopidogrel, ticagralol, low molecular weight heparin or second direct anticoagulant) is recently taken.
Patients undergoing needle EMG examination in EMG laboratory
Cohort
Prospective
Not listed
Intramuscular hematoma risk
Ultrasound evaluation of intramuscular hematoma formation after needle EMG in DOAC patients
Click on the lead sponsor to view all of their trials.
Masaryk University
Lead sponsor
Brno University Hospital
Collaborator
